286 related articles for article (PubMed ID: 30318624)
1. Once-daily vs twice-daily tacrolimus for de novo living kidney transplantation patients including ABO/HLA compatible and incompatible: A randomized trial.
Okumi M; Unagami K; Furusawa M; Kakuta Y; IIzuka J; Takagi T; Shirakawa H; Shimizu T; Omoto K; Inui M; Ishida H; Tanabe K
Clin Transplant; 2018 Dec; 32(12):e13423. PubMed ID: 30318624
[TBL] [Abstract][Full Text] [Related]
2. Protocol biopsy findings in living donor kidney transplant patients treated with once-daily or twice-daily tacrolimus formulation.
Masutani K; Tsuchimoto A; Haruyama N; Kitada H; Okabe Y; Noguchi H; Tanaka M; Tsuruya K; Kitazono T
Transplant Proc; 2014; 46(2):395-9. PubMed ID: 24655972
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open-label, noninferiority study.
Harland RC; Klintmalm G; Jensik S; Yang H; Bromberg J; Holman J; Kumar MSA; Santos V; Larson TJ; Wang X
Am J Transplant; 2020 Jan; 20(1):159-171. PubMed ID: 31509331
[TBL] [Abstract][Full Text] [Related]
4. Neither pre-transplant rituximab nor splenectomy affects de novo HLA antibody production after renal transplantation.
Ashimine S; Watarai Y; Yamamoto T; Hiramitsu T; Tsujita M; Nanmoku K; Goto N; Takeda A; Katayama A; Uchida K; Kobayashi T
Kidney Int; 2014 Feb; 85(2):425-30. PubMed ID: 23945498
[TBL] [Abstract][Full Text] [Related]
5. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial.
Rostaing L; Bunnapradist S; Grinyó JM; Ciechanowski K; Denny JE; Silva HT; Budde K;
Am J Kidney Dis; 2016 Apr; 67(4):648-59. PubMed ID: 26717860
[TBL] [Abstract][Full Text] [Related]
6. OSAKA trial: a randomized, controlled trial comparing tacrolimus QD and BD in kidney transplantation.
Albano L; Banas B; Klempnauer JL; Glyda M; Viklicky O; Kamar N;
Transplantation; 2013 Nov; 96(10):897-903. PubMed ID: 23982340
[TBL] [Abstract][Full Text] [Related]
7. ABO-incompatible pediatric kidney transplantation without antibody removal.
Kawamura T; Hamasaki Y; Takahashi Y; Hashimoto J; Kubota M; Muramatu M; Itabashi Y; Hyodo Y; Ohashi Y; Aikawa A; Sakai K; Shishido S
Pediatr Nephrol; 2020 Jan; 35(1):95-102. PubMed ID: 31673829
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data.
Qazi Y; Shaffer D; Kaplan B; Kim DY; Luan FL; Peddi VR; Shihab F; Tomlanovich S; Yilmaz S; McCague K; Patel D; Mulgaonkar S
Am J Transplant; 2017 May; 17(5):1358-1369. PubMed ID: 27775865
[TBL] [Abstract][Full Text] [Related]
9. Single fixed low-dose rituximab as induction therapy suppresses de novo donor-specific anti-HLA antibody production in ABO compatible living kidney transplant recipients.
Tomita Y; Iwadoh K; Ogawa Y; Miki K; Kato Y; Kai K; Sannomiya A; Koyama I; Kitajima K; Nakajima I; Fuchinoue S
PLoS One; 2019; 14(10):e0224203. PubMed ID: 31644555
[TBL] [Abstract][Full Text] [Related]
10. A randomized, open-label pharmacokinetic trial of tacrolimus extended-release dosing in obese de novo kidney transplant recipients.
Jasiak-Panek NM; Wenzler E; Patel S; Thielke JJ; Progar K; Patel S; Brandt S; Huang YJ; Benedetti E; West-Thielke PM
Clin Transplant; 2019 Aug; 33(8):e13640. PubMed ID: 31206808
[TBL] [Abstract][Full Text] [Related]
11. Outcome of desensitization in human leukocyte antigen- and ABO-incompatible living donor kidney transplantation: a single-center experience in more than 100 patients.
Al Meshari K; Pall A; Chaballout A; El Gamal H; Al Mana H; Humaidan H; Alzayer F; Al Talhi M
Transplant Proc; 2013 May; 45(4):1423-6. PubMed ID: 23726587
[TBL] [Abstract][Full Text] [Related]
12. Results of a multicenter prospective clinical study in Japan for evaluating efficacy and safety of desensitization protocol based on rituximab in ABO-incompatible kidney transplantation.
Takahashi K; Saito K; Takahara S; Fuchinoue S; Yagisawa T; Aikawa A; Watarai Y; Yoshimura N; Tanabe K; Morozumi K; Shimazu M;
Clin Exp Nephrol; 2017 Aug; 21(4):705-713. PubMed ID: 27534951
[TBL] [Abstract][Full Text] [Related]
13. Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial.
Budde K; Bunnapradist S; Grinyo JM; Ciechanowski K; Denny JE; Silva HT; Rostaing L;
Am J Transplant; 2014 Dec; 14(12):2796-806. PubMed ID: 25278376
[TBL] [Abstract][Full Text] [Related]
14. LCPT once-daily extended-release tacrolimus tablets versus twice-daily capsules: a pooled analysis of two phase 3 trials in important de novo and stable kidney transplant recipient subgroups.
Bunnapradist S; Rostaing L; Alloway RR; West-Thielke P; Denny J; Mulgaonkar S; Budde K
Transpl Int; 2016 May; 29(5):603-11. PubMed ID: 26953629
[TBL] [Abstract][Full Text] [Related]
15. Ten-year observational follow-up of a randomized trial comparing cyclosporine and tacrolimus therapy combined with steroid withdrawal in living-donor renal transplantation.
Kim J; Park J; Hwang S; Yoo H; Kim K; Park JB; Jang HR; Lee JE; Kim SJ; Kim YG; Kim DJ; Oh HY; Huh W
Clin Transplant; 2018 Sep; 32(9):e13372. PubMed ID: 30080284
[TBL] [Abstract][Full Text] [Related]
16. Comparison of pharmacokinetics and pathology for low-dose tacrolimus once-daily and twice-daily in living kidney transplantation: prospective trial in once-daily versus twice-daily tacrolimus.
Tsuchiya T; Ishida H; Tanabe T; Shimizu T; Honda K; Omoto K; Tanabe K
Transplantation; 2013 Jul; 96(2):198-204. PubMed ID: 23792649
[TBL] [Abstract][Full Text] [Related]
17. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
[TBL] [Abstract][Full Text] [Related]
18. Impact of HLA-identity on results of ABO-incompatible living kidney transplantation.
Shimmura H; Tanabe K; Tokumoto T; Ishida H; Ishikawa N; Miyamoto N; Shimizu T; Shirakawa H; Setoguchi K; Teraoka S; Toma H
Transplant Proc; 2004 Sep; 36(7):2172-4. PubMed ID: 15518790
[TBL] [Abstract][Full Text] [Related]
19. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
[TBL] [Abstract][Full Text] [Related]
20. Bioavailability and costs of once-daily and twice-daily tacrolimus formulations in de novo kidney transplantation.
Glander P; Waiser J; Kasbohm S; Friedersdorff F; Peters R; Rudolph B; Wu K; Budde K; Liefeldt L
Clin Transplant; 2018 Aug; 32(8):e13311. PubMed ID: 29888809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
